The FDA announced on July 31 that it had approved Epidiolex (cannabidiol or CBD) oral solution for the treatment of seizures associated with tuberous sclerosis complex in patients 1 year of age and older. Epidiolex had previously been approved by the FDA for the treatment of seizures in patients 2 years of age and older diagnosed with Lennox-Gastaut syndrome and Dravet syndrome, two serious and rare forms of epilepsy. Epidiolex, a marijuana-derived drug, is the first and only FDA-approved prescription CBD treatment. The DEA had originally placed Epidiolex in schedule V of the Controlled Substances Act. However, in April 2020, the DEA announced that it would be descheduling Epidiolex, and many states have announced that they have or will follow suit.